M. S. Clair

发表

Synthesis of 2-amino-9-(3′-azido-2′,3′-dideoxy-beta-D-erythro-pentofuranosyl)-6-methoxy-9H-purine (AzddMAP) and AzddGuo

J. Collins, G. A. Freeman, M. Almond, 1991 .

Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review

J. Gatell, M. Aboud, V. Vannappagari, 2019, Antiviral therapy.

HIV & Hepatitis in the Americas 28–30 April 2016, Mexico City, Mexico

N. Volkow, K. Tashima, D. Podzamczer, 2016, Journal of the International AIDS Society.

Evaluation of a Real-Time Nucleic Acid Sequence-Based Ampliﬁcation Assay Using Molecular Beacons for Detection of Human Immunodeﬁciency Virus Type 1

D. Mcclernon, M. S. Clair, C. Vavro, 2006 .

In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeﬁciency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV (cid:1)

E. Furfine, L. Boone, P. Yates, 2007 .

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

H. Stellbrink, A. Lazzarin, J. Reynes, 2013, AIDS (London).

Synthesis, anti-human immunodeficiency virus, and anti-hepatitis B virus activity of pyrimidine oxathiolane nucleosides

R. Schinazi, D. Liotta, G. Painter, 1993 .

The synthesis and anti-hiv activity of pyrimidine dioxolanyl nucleosides

R. Schinazi, D. Liotta, G. Painter, 1993 .

Nucleoside and Nucleotide Analogue Reverse Transcriptase Inhibitors: A Clinical Review of Antiretroviral Resistance

Joel E Gallant, R. Haubrich, D. Richman, 2002, Antiviral therapy.

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

D. Podzamczer, B. Clotet, H. Stellbrink, 2017, The Lancet.

Novel 6-Alkoxypurine 2′,3′-Dideoxynucleosides, e.g. (I), as Inhibitors of the Cytopathic Effect of the Human Immunodeficiency Virus.

L. Frick, T. Spector, M. English, 1994 .

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.

J. Eron, Kimberly Smith, W. Spreen, 2015, The Lancet. Infectious diseases.

Evolution of HIV Resistance Mutations in Patients Maintained on a Stable Treatment Regimen After Virologic Failure

M. Ferguson, W. O'brien, D. Mcclernon, 2006, Journal of acquired immune deficiency syndromes.

Phenotypic impact of HIV reverse transcriptase M184I/V mutations in combination with single thymidine analog mutations on nucleoside reverse transcriptase inhibitor resistance

C. Chappey, N. Parkin, M. Bates, 2004, AIDS.

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

D. Kuritzkes, J. Schapiro, J. Polli, 2021, AIDS.

HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention.

J. Mellors, M. Marzinke, R. Landovitz, 2022, The Journal of infectious diseases.

AVT 8(6) in progress

R. Haubrich, D. Richman, M. Wainberg, 2003 .

Transmission of Integrase Strand-Transfer Inhibitor Multidrug-Resistant HIV-1: Case Report and Response to Raltegravir-Containing Antiretroviral Therapy

C. Petropoulos, B. Ha, B. Young, 2011, Antiviral therapy.

In-Vitro Resistance to Zidovudine and Alpha-interferon in HIV-1 Isolates from Patients: Correlations with Treatment Duration and Response

R. Weinstein, B. Edlin, P. Pitha, 1992, Annals of Internal Medicine.

Antiviral Efficacy of Abacavir in Antiretroviral Therapy-Experienced Adults Harbouring HIV-1 with Specific Patterns of Resistance to Nucleoside Reverse Transcriptase Inhibitors

S. Hetherington, G. Pearce, W. Spreen, 2004, Antiviral therapy.

1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity

L. Boone, M Tisdale, M. Tisdale, 1997, Antimicrobial agents and chemotherapy.

Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89

E. Garvey, M. S. St. Clair, M. S. Clair, 1997, Antimicrobial agents and chemotherapy.

Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.

M. Lederman, D. Kuritzkes, J. Leonard, 1998, The Journal of infectious diseases.

Pilot Study of Once-Daily Simplification Therapy with Abacavir/Lamivudine/Zidovudine and Efavirenz for Treatment of HIV-1 Infection

D. Ward, P. Ruane, D. Berger, 2006, HIV clinical trials.

Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HAART and higher viremia

N. Graham, L. Ross, R. Demasi, 2000, AIDS.

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.

J W Mulder, R. Schooley, P. Harrigan, 1996, The Journal of infectious diseases.

Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine

R F Schinazi, R. Schinazi, G. Painter, 1992, Antimicrobial Agents and Chemotherapy.

Inhibition of herpes simplex virus-induced DNA polymerase activity and viral DNA replication by 9-(2-hydroxyethoxymethyl)guanine and its triphosphate

G. Elion, P. Keller, P. Furman, 1979 .

141W94 : ANTI-HIV

B. Sadler, S. Pazhanisamy, G. Painter, 1996 .

Effect of influenza immunization on immunologic and virologic characteristics of pediatric patients infected with human immunodeficiency virus.

K. N. Pennington, S. Katz, S. Katz, 1997, The Pediatric infectious disease journal.